Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

The Centers for Medicare & Medicaid Services (CMS) has added several changes to the Medicare price negotiation process ...

If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...

Vance breaks down his viral ‘Jim Halpert’ side-smirk moment at VP debate Ohio Senator JD Vance's frequent glances at the camera during the vice presidential debate sparked viral comparisons to ...